Polymersomes conjugated with des-octanoyl ghrelin for the delivery of therapeutic and imaging agents into brain tissues

Biomaterials

Volumn 35, Issue 6, 2014, Pages 2051-2065

  Chen, Yung Chu ^a,b   Chiang, Chi Feng ^a   Chen, Li Fang ^c   Liao, Shu Chuan ^a,d   Hsieh, Wen Yuan ^b   Lin, Win Li ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d MING CHI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Blood brain barrier (BBB); Brain delivery; Des octanoyl ghrelin; Nanomedicine; Polymersomes; Targeting

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN DELIVERY; GHRELIN; POLYMERSOMES; TARGETING;

BLOOD; ETHYLENE GLYCOL; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY;

FUNCTIONAL POLYMERS;

COPOLYMER; COURMAIN 6 DYE; CY5.5 DYE; DES OCTANOYL GHRELIN; DES OCTANOYL GHRELIN POLY(ETHYLENE GLYCOL G GLUTAMATE) CO POLY(DISTEARIN G GLUTAMATE); FLUORESCENT DYE; GHRELIN; METENKEPHALIN; POLY(CARBOXYL ETHYLENE GLYCOL G GLUTAMATE) CO POLY(DISTEARIN G GLUTAMATE); POLY(GLUTAMIC SUCCINIMIDYL ESTER) CO POLY(DISTEARIN G GLUTAMATE); POLY(METHYL ETHYLENE GLYCOL G GLUTAMATE) CO POLY(DISTEARIN G GLUTAMATE); POLYGLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; ASTROCYTE; BINDING SITE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELLS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; FLUORESCENCE IMAGING; HOT PLATE TEST; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; SPLEEN;

ANIMALIA;

BLOOD-BRAIN BARRIER (BBB); BRAIN DELIVERY; DES-OCTANOYL GHRELIN; NANOMEDICINE; POLYMERSOMES; TARGETING;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GHRELIN; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, THEORETICAL; NANOMEDICINE; POLYMERS; RATS;

EID: 84890249205     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.051     Document Type: Article

References (65)

1. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004, 104(1):29-45.
2. Banks W.A., Kastin A.J. Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 1996, 59(23):1923-1943.
3. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004, 25(8):423-429.
4. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2(1):3-14.
5. Pardridge W.M. Blood-brain barrier delivery. Drug Discov Today 2007, 12(1-2):54-61.
6. Liu X., Chen C. Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov 2005, 8(4):505-512.
7. Béduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28(33):4947-4967.
8. Visser C.C., Voorwinden H., Crommelin D.J.A., Danhof M., Boer A.G. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res 2004, 21(5):761-769.
9. Pardridge W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2005, 2(1):129-138.
10. Li J., Feng L., Fan L., Zha Y., Guo L., Zhang Q., et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32(21):4943-4950.
11. Yang F.Y., Wong T.T., Teng M.C., Liu R.S., Lu M., Liang H.F., et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor in glioblastoma. JControl Release 2012, 160(3):652-658.
12. Kojima M., Kangawa K. Ghrelin: structure and function. Physiol Rev 2005, 85(2):495-522.
13. Peeters T.L. Ghrelin: a new player in the control of gastrointestinal functions. Gut 2005, 54(11):1638-1649.
14. St Pierre D.H., Wang L., Taché Y. Ghrelin: a novel player in the gut-brain regulation of growth hormone and energy balance. News Physiol Sci 2003, 18:242-246.
15. Van der Lely A.J., Tschöp M., Heiman M.L., Ghigo E. Biological physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004, 25(3):426-457.
16. Korbonits M., Goldstone A.P., Gueorguiev M., Grossman A.B. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 2004, 25(1):27-68.
17. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402(6762):656-660.
18. Hotta M., Ohwada R., Katakami H., Shibasaki T., Hizuka N., Takano K. Plasma levels of intact and degraded ghrelin and their responses to glucose infusion in anorexia nervosa. JClin Endocrinol Metab 2004, 89(11):5707-5712.
19. Wiedmer P., Nogueiras R., Broglio F., D'Alessio D., Tschöp M.H. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007, 3(10):705-712.
20. Tschöp M., Weyer C., Tataranni P.A. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50(4):707-709.
21. Talukder M.J., Takeuchi T., Harada E. Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. JVet Med Sci 2003, 65(9):957-964.
22. Baldwin G.S., Bacic T., Chandler R., Grego B., Pedersen J., Simpson R.J., et al. Isolation of transferrin from porcine gastric mucosa: comparison with porcine serum transferrin. Comp Biochem Physiol B 1990, 95(2):261-268.
23. Banks W.A., Tschöp M., Robinson S.M., Heiman M.L. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. JPharmacol Exp Ther 2002, 302(2):822-827.
24. Gosk S., Vermehren C., Storm G., Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. JCereb Blood Flow Metab 2004, 24(11):1193-1204.
25. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002, 54(4):561-587.
26. Pang Z., Lu W., Gao H., Hu K., Chen J., Zhang C., et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. JControl Release 2008, 128(2):120-127.
27. Ji B., Maeda J., Higuchi M., Inoue K., Akita H., Harashima H. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006, 78(8):851-855.
28. Kurosaki T., Kitahara T., Kawakami S., Higuchi Y., Yamaguchi A., Nakagawa H., et al. γ-Polyglutamic acidcoated vectors for effective and safe gene therapy. JControl Release 2010, 142(3):404-410.
29. Liang H.F., Yang T.F., Huang C.T., Chen M.C., Sung H.W. Preparation of nanoparticles composed of poly(γ-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. JControl Release 2005, 105(3):213-225.
30. Kuo Y.C., Yu H.W. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid). Int J Pharm 2011, 416(1):365-375.
31. Kuo Y.C., Yu H.W. Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field. Colloids Surf B Biointerfaces 2011, 88(2):627-634.
32. Discher D.E., Eisenberg A. Polymer vesicles. Science 2002, 297:967-973.
33. Discher D.E., Ahmed F. Polymersomes. Annu Rev Biomed Eng 2006, 8:323-341.
34. Bermudez H., Brannan A.K., Hammer D.A., Bates F.S., Discher D.E. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules 2002, 35(21):8203-8208.
35. Ahmed F., Discher D.E. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. JControl Release 2004, 96(1):37-53.
36. Meng F., Engbers G.H.M., Feijen J. Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting. JControl Release 2005, 101(1-3):187-198.
37. Photos P.J., Bacakova L., Discher B., Bates F.S., Discher D.E. Polymer vesicles invivo: correlations with PEG molecular weight. JControl Release 2003, 90(3):323-334.
38. Discher D.E., Ortiz V., Srinivas G., Klein M.L., Kim Y., Christian D., et al. Emerging applications of polymersomes in delivery: from molecular dynamics to shrinkage of tumors. Prog Polym Sci 2007, 32(8-9):838-857.
39. Upadhyay K.K., Bhatt A.N., Mishra A.K., Dwarakanath B.S., Jain S., Schatz C., et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010, 31(10):2882-2892.
40. Pang Z., Feng L., Hua R., Chen J., Gao H., Pan S., et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 2010, 7(6):1995-2005.
41. Gao H.L., Pang Z.Q., Fan L., Hu K.L., Wu B.X., Jiang X.G. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: invitro and invivo evaluations. Acta Pharmacol Sin 2010, 31(2):237-243.
42. Nie T., Zhao Y., Xie Z.W., Wu C. Micellar formation of poly(caprolactone-block-ethylene oxide-block-caprolactone) and its enzymatic biodegradation in aqueous dispersion. Macromolecules 2003, 36(23):8825-8829.
43. Burchard W., Patterson G.D. Light scattering from polymers 1983, Springer-Verlag, Berlin.
44. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: invitro and invivo evaluations. JControl Release 2009, 134(1):55-61.
45. Bickel U., Yoshikawa T., Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001, 46(1-3):247-279.
46. Schmauss C., Yaksh T.L. Invivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differencial association of mu, delta and kappa receptors with visceral, chemicaland cutaneos thermal stimuli in the rat. JPharmacol Exp Ther 1984, 228(1):1-12.
47. Jensen T.S., Yaksh T.L. Comparison of antinociceptive action of morphine in the periaqueductal gray medial and paramedial medulla in rat. Brain Res 1986, 363(1):99-113.
48. Elyad M., Davidson M.D., Doursout M.F., Peter S., Jacques E., Chelly M.D. Antinociceptive and cardiovascular properties of esmolol following formalin injection in rats. Can J Anaesth 2001, 48(1):59-64.
49. Calvo P., Gouritin B., Villarroya H., Eclancher F., Giannavola C., Klein C., et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 2002, 15(8):1317-1326.
50. Afergan E., Epstein H., Dahan R., Koroukhov N., Rohekar K., Danenberg H. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. JControl Release 2008, 132(2):84-90.
51. Moghimi S., Hunter A., Murray J. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 17:283-318.
52. Storm G., Belliot S., Daemen T., Lasic D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995, 17:31-48.
53. Loging W., Lal A., Siu I., Loney T., Wikstrand C., Marra M. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 2000, 10(9):1393-1402.
54. Lammers T., Kiessling F., Hennink W., Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010, 7(6):1899-1912.
55. Parveen S., Sahoo S.K. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 2011, 670(2-3):372-383.
56. Parveen S., Mitra M., Krishnakumar S., Sahoo S.K. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta Biomater 2010, 6(8):3120-3131.
57. Torchilin V. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(2):145-160.
58. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-D-a-Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31(30):7748-7757.
59. Delhanty P.J., Sun Y., Visser J.A., van Kerkwijk A., Huisman M., van Ijcken W.F., et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE 2010, 5:e11749.
60. Miegueu P., St Pierre D., Broglio F., Cianflone K. Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. JCell Biochem 2011, 112:704-714.
61. Baragli A., Ghe C., Arnoletti E., Granata R., Ghigo E., Muccioli G. Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase g and phosphodiesterase 3B. Biochim Biophys Acta 2011, 1811:386-396.
62. Granata R., Settanni F., Biancone L., Trovato L., Nano R., Bertuzzi F., et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic b-cells and human islets: involvement of 30,50-cyclic adenosine monophosphate/protein kinase A, extracellular signalregulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology 2007, 148:512-529.
63. Cederberg H., Rajala U., Koivisto V.M., Jokelainen J., Surcel H.M., Keinanen-Kiukaanniemi S., et al. Unacylated ghrelin is associated with changes in body composition and body fat distribution during long-term exercise intervention. Eur J Endocrinol 2011, 165:243-248.
64. Gauna C., Delhanty P.J., van Aken M.O., Janssen J.A., Themmen A.P., Hofland L.J., et al. Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol Cell Endocrinol 2006, 251:103-111.
65. Halem H.A., Taylor J.E., Dong J.Z., Shen Y., Datta R., Abizaid A., et al. Anovel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weightgain. Neuroendocrinology 2005, 81:339-349.